# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receiv...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...
Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $8 ...
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announc...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...